Abstract
In the past two decades, there has been sudden development in antiepileptic drugs (AEDs) for the adjunctive treatment of epilepsy. CNB is a leading-edge new generation tetrazole-derived carbamate for the treatment of focal-onset epileptic seizures where the mode of action is mediated by blocking voltage-gated sodium channels and interaction with the GABAergic system. The US FDA approved CNB with new hope for superior control over seizure, better safety, and tolerability profile compared to earlier AEDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
